JAK Inhibition in COVID-19
Cross-source consensus on JAK Inhibition in COVID-19 from 1 sources and 4 claims.
1 sources · 4 claims
Benefits
Background
Evidence quality
Highlighted claims
- A meta-analysis of four baricitinib RCTs in 10,815 hospitalised COVID-19 patients demonstrated a significant reduction in 28-day mortality. — Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic
- The FDA granted emergency authorisation for baricitinib combined with remdesivir for hospitalised COVID-19 patients requiring respiratory support. — Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic
- A meta-analysis of all JAK/STAT inhibition data from COVID-19 studies is proposed to identify which patient subgroups benefit most. — Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic
- Early pandemic data from China and Italy suggested that JAK inhibitors could rapidly resolve symptoms in severe COVID-19. — Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic